Industry Overview

North American brachytherapy market was valued at $818.1 million in 2025 and is projected to reach $1,670.3 million by 2035, growing at a CAGR of 7.4% during the forecast period (2026-2035). The market is witnessing steady growth, driven by rising cancer prevalence, growing adoption of minimally invasive cancer treatment procedures, and technological advancements in radioactive implants and imaging guidance. The US dominates the market due to its advanced healthcare infrastructure, strong presence of key players, and high adoption of image-guided and high-dose-rate (HDR) brachytherapy procedures for prostate, gynecological, and breast cancers. Furthermore, continuous innovation in radiotherapy technologies and supportive regulatory approvals are expected to enhance treatment precision and patient outcomes, bolstering market expansion across North America.

Market Dynamics

Clinical Advantage and Patient Outcomes

Brachytherapy delivers very high, localized radiation doses with a steep dose fall-off, which improves local tumour control while sparing surrounding healthy tissue. This translates into shorter overall treatment times, lower cumulative toxicity and often better post-treatment quality of life for prostate and gynecologic cancer patients compared with protracted external-beam regimens. Those clinical benefits drive physician preference and patient demand—especially for cases where organ preservation and rapid recovery are priorities—and sustain procedure volumes across cancer centres and ambulatory clinics.

Technology and Workflow Innovation

Continuous improvements in MRI/CT-guided planning, 3D-printed and modular applicators, automated afterloaders, real-time dosimetry and the rise of electronic brachytherapy are expanding the range of treatable indications and simplifying procedural workflows. Better imaging and planning software increase accuracy and reproducibility, reducing procedure time and complication rates, while newer devices lower shielding requirements and expand the settings where procedures can safely occur. As hospitals and ASCs upgrade equipment, recurring consumables and software/licenses create steady, higher-margin revenue streams for suppliers.

Reimbursement, Care-Setting Economics and Adoption Models

Favorable reimbursement pathways for same-day HDR and seed implant procedures, together with the growing role of ambulatory surgery centres, make brachytherapy an economically attractive option for providers. Shorter treatment courses improve throughput and can lower overall episode costs an advantage under value-based payment models and bundled care arrangements. Where payers recognize these cost and outcome benefits, hospitals and oncology networks are more willing to invest in capital equipment and training, accelerating regional adoption and market growth.

Market Segmentation

• Based on the indication, the market is segmented into breast cancer, gynecological cancer, prostate cancer, skin cancer, brain cancer, and others.
• Based on the type, the market is segmented into low-dose rate (LDR) brachytherapy and high-dose rate (HDR) brachytherapy.

High-Dose Rate (HDR) Segment to Lead the Market with the Largest Share

Among all segments, high-dose rate (HDR) brachytherapy is expected to lead the North American Brachytherapy Market with the largest share during the forecast period. The dominance of this segment is primarily attributed to its clinical efficiency, shorter treatment times, and ability to deliver precise, high doses of radiation to target tumors while minimizing exposure to surrounding healthy tissues. HDR brachytherapy is widely adopted in the treatment of prostate, breast, cervical, and skin cancers, which are among the most prevalent cancer types in the region. The growing preference for outpatient and minimally invasive procedures across the US and Canada has further propelled the adoption of HDR systems, as they offer superior dosimetric accuracy, improved patient comfort, and reduced hospital stays compared to low-dose alternatives.

Additionally, advancements in image-guided and remote afterloading technologies have enhanced the safety and precision of HDR brachytherapy, driving its clinical preference among oncologists. Supportive reimbursement policies, increased investments in radiotherapy infrastructure, and growing awareness of brachytherapy’s therapeutic benefits are also contributing to the segment’s robust growth. Overall, HDR brachytherapy continues to set the benchmark for modern cancer radiotherapy in North America due to its flexibility, effectiveness, and technological innovation.

Prostate Cancer: A Key Segment in Market Growth

Among the indications, prostate cancer represents the key segment driving growth in the North American brachytherapy market. This dominance is attributed to the high prevalence of prostate cancer across the region, particularly in the United States and Canada, where it remains one of the most commonly diagnosed cancers among men. The growing preference for minimally invasive treatment options that provide localized radiation with minimal damage to surrounding tissues has increased the adoption of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy in prostate cancer management.

Moreover, advancements in imaging guidance technologies such as MRI and ultrasound have significantly improved the precision and safety of brachytherapy procedures, further supporting their use in prostate cancer treatment. The favorable reimbursement framework for prostate brachytherapy procedures in North America and the proven long-term efficacy of this therapy in achieving high disease control rates with limited side effects have also contributed to market expansion. Additionally, increasing awareness among patients and healthcare providers about brachytherapy’s shorter hospital stays and faster recovery times compared to external beam radiation therapy (EBRT) is propelling its utilization. With ongoing research into novel isotopes and improved seed delivery systems, prostate brachytherapy is expected to maintain a strong growth trajectory over the forecast period. The combination of clinical effectiveness, cost efficiency, and rising prostate cancer incidence positions this indication as the most significant contributor to the growth of the North American brachytherapy market.

Regional Outlook

The North America brachytherapy market is further divided by countries, including US, Canada and the Rest of North America.

North America Dominates the North America Market

In North America, the US dominates the North American brachytherapy market with a major share, driven by its advanced healthcare infrastructure, high cancer prevalence, strong reimbursement policies, and early adoption of innovative treatment technologies. The country accounts for the largest proportion of brachytherapy procedures in the region, primarily due to the increasing incidence of cancers such as prostate, breast, cervical, and skin cancers, which are effectively managed through targeted radiation therapy. According to data from the American Cancer Society, prostate cancer continues to be among the most common cancers in American men, fueling the use of both low-dose rate (LDR) and high-dose rate (HDR) brachytherapy. Additionally, the presence of well-established cancer treatment centers and oncology departments across the US ensures the availability of skilled professionals and state-of-the-art equipment required for performing complex brachytherapy procedures.

The market also benefits from strong support from governmental and private funding agencies that promote cancer research and the development of advanced radiotherapy systems. Major players in the brachytherapy sector, such as Varian Medical Systems, Elekta AB, and Becton, Dickinson and Company, have a significant operational base in the US, providing continuous innovation, clinical trials, and product availability. Moreover, the US Food and Drug Administration (FDA) plays a key role in fostering market growth by streamlining regulatory approvals for new brachytherapy devices and isotopes. Increased awareness campaigns and screening programs for early cancer detection, along with favorable reimbursement from Medicare and private insurers, have further expanded patient access to brachytherapy treatments.

Additionally, the rise in outpatient cancer treatment facilities and the growing shift toward minimally invasive and cost-effective therapies have accelerated the adoption of brachytherapy across diverse indications. With ongoing advancements in image-guided and real-time adaptive brachytherapy systems, the US is expected to maintain its leadership in the North American market, contributing significantly to the region’s overall revenue share during the forecast period.

Market Players Outlook

The major companies operating in the North America brachytherapy market include Becton, Dickinson and Company (BD), Elekta AB, Eckert & Ziegler BEBIG, Theragenics Corp., Varian Medical Systems, Inc., among others. The companies are pursuing partnerships, collaborations, mergers, and acquisitions to drive innovation, expand product portfolios, enhance sustainability, and strengthen market presence. These strategies enable players to respond to growing demand for energy-efficient, high-performance insulation solutions across residential, commercial, and industrial applications while maintaining a competitive edge.

Recent Developments

• In October 2024, a Cancer patient was treated in Canada with actinium-225 DOTATATE, a rare radioisotope, as part of a clinical trial for neuroendocrine tumours (NETs). This theranostic therapy combines diagnostic imaging with radiation to locate and eradicate tumours. The trial, involving only three centres in Canada, will compare actinium-225 DOTATATE's efficacy and safety against standard therapies for patients with disease progression post-conventional treatment. Actinium-225 uses potent alpha particles that effectively target cancer cells due to their high energy density.

The Report Covers

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the North America brachytherapy market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.